PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Multicentre, Double-Blind, Double-Dummy, Randomised Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Diclofenac Sodium in Patients Undergoing Knee Arthroscopy for Anterior Cruciate Ligament (ACL) Reconstruction
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2008-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 328
- Registration Number
- NCT00650598
- Locations
Pfizer Investigational Site
A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery
Phase 3
Terminated
- Conditions
- Pain
- Interventions
- Drug: Parecoxib/ValdecoxibDrug: Placebo
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 91
- Registration Number
- NCT00651300
- Locations
- π¦πΊ
Pfizer Investigational Site, Perth, Western Australia, Australia
A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 130
- Registration Number
- NCT00648258
- Locations
- π¨π³
Pfizer Investigational Site, Taipei, Taiwan
A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis
Phase 3
Completed
- Conditions
- Bronchitis, Chronic
- Interventions
- Drug: Amoxicillin/clavulinic acid
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT00649831
- Locations
- π«π·
Pfizer Investigational Site, Yerres, France
A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7
- Registration Number
- NCT00647907
- Locations
- π¨π³
Pfizer Investigational Site, Taipei, Taiwan
A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 197
- Registration Number
- NCT00647829
- Locations
- πΊπΈ
Pfizer Investigational Site, Boca Raton, Florida, United States
Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 340
- Registration Number
- NCT00649610
- Locations
- π»πͺ
Pfizer Investigational Site, Caracas, Venezuela
Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 458
- Registration Number
- NCT00648141
- Locations
- π©πͺ
Pfizer Investigational Site, Winsen/Luhe, Germany
An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia
Phase 3
Completed
- Conditions
- Pneumonia
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 139
- Registration Number
- NCT00648726
- Locations
- π¨π³
Pfizer Investigational Site, Shanghai, China
A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1549
- Registration Number
- NCT00649090
- Locations
- π§πͺ
Pfizer Investigational Site, Yvoir, Belgium
Β© Copyright 2025. All Rights Reserved by MedPath